Drug Res (Stuttg) 2017; 67(07): 419-424
DOI: 10.1055/s-0043-106586
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Evidence for the Involvement of Monoaminergic Pathways in the Antidepressant-Like Activity of Cymbopogon citratus in Mice

Solomon Umukoro
1   Neuropharmacology Unit, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
,
Somtochukwu I. Ogboh
1   Neuropharmacology Unit, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
,
Osarume Omorogbe
1   Neuropharmacology Unit, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
,
Abdul-lateef A. Adekeye
1   Neuropharmacology Unit, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
,
Matthew O. Olatunde
1   Neuropharmacology Unit, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
› Author Affiliations
Further Information

Publication History

received 26 December 2016

accepted 14 March 2017

Publication Date:
12 May 2017 (online)

Abstract

Objectives Depression is a complex neuropsychiatric disorder, which affects the quality of life of the sufferers and treatment approach is associated with serious adverse effects and sometimes therapeutic failures. Cymbopogon citratus leaf (CC) has been reported to exert anti-depressant effect but its mechanism of action is yet to be elucidated hence, the need for this study.

Methods The anti-depressant-like effect of Cymbopogon citratus aqueous leaf was evaluated using forced swim test (FST), tail suspension test (TST) and yohimbine-induced lethality test (YLT) in aggregated mice. Interaction studies involving p-chlorophenylalanine (pCPA), an inhibitor of serotonin biosynthesis and yohimbine, α2-adrenergic receptor antagonist were carried out to evaluate the role of monoaminergic system in the anti-depressant-like effect of CC. The effect of CC on spontaneous motor activity (SMA) was also assessed using activity cage.

Results Cymbopogon citratus (25 and 50 mg/kg, p.o.) demonstrated antidepressant-like activity devoid of significant stimulation of the SMA in mice. However, the antidepressant-like property of CC was significantly (p<0.05) attenuated by pretreatment with yohimbine suggesting involvement of noradrenergic pathway in the action of the extract. Also, pCPA reversed the anti-immobility effect of CC, indicating the role of serotonergic system in the mediation of its antidepressant activity. Moreover, CC (25 and 50 mg/kg) potentiated the lethal effect of yohimbine in aggregated mice, which further suggest the involvement of monoaminergic systems in its action.

Conclusions The results of the study showed that C. citratus might be interacting with serotonergic and noradrenergic pathways to mediate its anti-depressant-like effect in mice.

 
  • References

  • 1 Andrade L, Caraveo-Anduaga JJ, Berglund P. et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003; 12: 3-21
  • 2 Kessler RC, Bromet EL. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34: 119-138
  • 3 Kessler RC, Berglund P, Demler O. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602
  • 4 Krishman V, Nestler FJ. The molecular microbiology of depression. Nature 2008; 455: 894-902
  • 5 Nestler FJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiat 2006; 59: 1151-1159
  • 6 Anisman H, Zacharko RM. Multiple neurochemical and behavioralconsequences of stressors: Implications for depression. In: Anisman H, Zachark RM. (Eds.). Psychopharmacology of anxiolytics asants. Vol. 2: 2nd ed.1991: New York: Pergamon Press; 57–82
  • 7 Blair-West GW, Cantor CH, Mellsop GW. et al. Lifetime suicide risk in major depression: Sex and age determinants. Journal of Affective Disorders 1999; 55: 171-178
  • 8 Penn E, Tracy DK. The drugs don’t work? antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2012; 2: 179-188
  • 9 Kumari R, Agrawal A, Dubey GP. Role of medicinal plants with antidepressant action and its mechanism: a review. Pharmaceutical and Biological Evaluations 2016; 3: 70-82
  • 10 Avoseh O, Oyedeji O, Rungqu P. et al. Cymbopogon Species; Ethnopharmacology, phytochemistry and the pharmacological importance. Molecules 2015; 20: 7438-7453
  • 11 Shah RS. Scientific basis for the therapeutic use of Cymbopogon citratus. Journal of Advanced Pharmaceutical Technology & Research 2011; 3-8
  • 12 Moreira FV, Bastos JF, Blank AF. et al. Chemical composition and cardiovascular effects induced by the essential oil of Cymbopogon citratus DC. Stapf, Poaceae, in rats. Rev Bras Farmacogn 2010; 20: 904-909
  • 13 Gbenou JD, Ahounou JF, Akakpo HB. et al. Phytochemical composition of Cymbopogon citratus and Eucalyptus citriodora essential oils and their anti-inflammatory and analgesic properties on Wistar rats. Mol Biol Rep 2013; 40: 1127-1134
  • 14 Figueirinha A, Paranhos A, Perez-Alonso J. et al. Cymbopogon citratus leaves: Characterisation of flavonoids by HPLC-PDA-ESI/MS/MS and an approach to their potential as a source of bioactive polyphenols. Food Chem 2008; 110: 718-728
  • 15 Puatanachokchai R, Kishida H, Denda A. et al. Inhibitory effects of lemon grass (Cymbopogon citratus, Stapf) extract on the early phase of hepatocarcinogenesis after initiation with diethylnitrosamine in male rats. Cancer Lett 2002; 183: 9-15
  • 16 Dudhgaonkar MM. Evaluation of anti-depressant effect of lemon grass (Cymbopogon citratus) in albino mice. International Journal of Basic & Clinical Pharmacology 2014; 656-660
  • 17 Blanco MM, Costa CA, Freire AO. et al. Neurobehavioural effects of essential oils of Cymbopogon citratus in mice. Phytomedicine 2009; 16: 265-270
  • 18 Akande IS, Samuel TA, Agbazue U. et al. Comparative proximate analysis of ethanolic and water extracts of Cymbopogon citratus (lemongrass) and four tea brands. Plant Sci Res 2011; 3: 29
  • 19 Porsolt RD, Anton G, Deniel M. et al. Behavioural Despair in rats: A new Animal Model sensitive to Antidepressant Treatments. European Journal of Pharmacology 1978; 47: 379-391
  • 20 Cryan JP, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625
  • 21 Ulak G, Mutlu O, Tanyeri P. et al. Involvement of serotonin receptor subtypes in the antidepressant-like effect of trim in the rat forced swimming test. 2010; Pharmacology, Biochemistry and Behavior 95: 308-314
  • 22 Malick JB. Potentiation of yohimbine-induced lethality in mice: predictor of antidepressant potential. Drug Dev Res 1983; 3: 357-363
  • 23 Sherman AD, Sacquitne JL, Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982; 16: 449-454
  • 24 Cryan JF, Slattery DA. Animal models of mood disorders: Recent developments. Curr Opin Psychiatry 2007; 20: 1-7
  • 25 Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625
  • 26 Kang S, Kim HJ, Shin SK. et al. Effects of reboxetine and citalopram pretreatment on changes in cocaine and amphetamine regulated transcript (CART) expression in rat brain induced by the forced swimming test. Eur J Pharmacol 2010; 647: 110-116
  • 27 Quinton RM. The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br J Pharmacol Chemother 1963; 21: 51-66
  • 28 Goldberg MR, Robertson D. Yohimbine: A pharmacological probe for study of the α2-adrenoceptor. Pharmacol Rev 1983; 35: 143 -180
  • 29 Siqueira IR, Lara FS, Silva DR. et al. Psychopharmacological properties of Ptychopetalum olacoides Bentham (Olacacaeae). Pharm Biol 1998; 36: 327 -334
  • 30 Kirby LG, Lucki I. Interaction between the forced swimming test and fl uoxetine treatment on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the Rat. J Pharmacol Exp Ther 1997; 282: 967-976
  • 31 Cryan JF, Page ME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology 2005; 182: 335-344
  • 32 Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology 2005; 177: 245-255
  • 33 Taylor C, Fricker AD, Devi LA. et al. Mechanisms of action of antidepressants: From neurotransmitter systems to signaling pathways. Cell Signal 2005; 17: 549-557
  • 34 O’Leary OF, Bechtholt AJ, Crowley JJ. et al. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in t he mouse tail suspension test. Psychopharmacology 2007; 192: 357-371
  • 35 Delgado PL, Miller HL, Salomon RM. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry 1999; 46: 212-220